Table 4 Antibiotic resistance pattern of the prevalent Gram-positive pathogens isolated from patients admitted in ICU, Ain Shams University Hospitals, Egypt, March 2018-February 2019
Antibiotic | Resistant isolates, n (%) | Total , n/N(%) (N = 381) | p value | ||
|---|---|---|---|---|---|
Staphylococcus aureus (n = 69) | Coagulase-negative staphylococci (n = 161) | Enterococcus spp. (n = 151) | |||
Amikacin | 34 (49.29) | 61 (37.88) | **NA | 95/230 (41.30) | 0.108 |
Ampicillin | NA ***67 | NA ***156 | 98 (64.90) | 321/381 (84.25) | – |
Cefoxitin | 51 (73.91) | 125 (77.63) | **NA | 176/230 (76.52) | 0.541 |
Penicillin | 67 (97.10) | 156 (96.89) | 118 (78.14) | 341/381 (89.50) | p < 0.001* |
Clindamycin | 36 (52.17) | 97 (60.2) | **NA | 133/230 (57.82) | 0.256 |
Erythromycin | 43 (62.31) | 130 (80.74) | 147 (62.31) | 320/381 (83.98) | p < 0.001* |
Ciprofloxacin | 36 (52.17) | 107 (66.45) | 131 (86.75) | 274/381 (71.91) | p < 0.00*1 |
Doxycycline | 29 (42.02) | 70 (43.47) | 38 (25.16) | 137/381 (35.95) | 0.002* |
Gentamicin (low dose) | 51 (73.91) | 98 (51.30) | **NA | 149/230 (64.78) | 0.058 |
Gentamicin (high dose) | **NA | **NA | 95 (62.91) | 95/151 (62.91) | – |
Linezolid | 0 (0) | 0 (0) | 0 (0) | 0/381 (0) | – |
Levofloxacin | 33 (47.82) | 97 (60.24) | 115 (76.15) | 245/381 (64.30) | 0.001* |
Teicoplanin | 6 (8.69) | 25 (15.52) | 26 (17.21) | 57/381 (14.96) | 0.250 |
Tetracycline | 38 (55.07) | 76 (47.20) | 53 (35.09) | 167/381 (43.83) | 0.011* |
Tobramycin | 40 (57.97) | 117 (72.67) | **NA | 157/230 (68.26 | 0.028* |
Trimethoprim/sulfamethoxazole | 10 (14.49) | 100 (62.11) | **NA | 110/230 (47.82) | p < 0.001* |
Nitrofurantoin | 0 (0) | 4 (20.00) | 38 (28.12) | 42/99 (42.42) | 0.021* |
Vancomycin | 0 (0) | 0 (0) | 10 (6.62) | 10/381 (2.62) | – |
No. of urine samples | 5 | 20 | 74 | 99 | |